A new monitoring protocol using troponin and CRP provides guidance on continuing or ceasing clozapine in patients at risk for clozapine-induced myocarditis.
This protocol recommends active monitoring for 4 weeks, relying predominantly on troponin and C-reactive protein results. It encourages continuation of clozapine in the presence of mild illness, but defines a threshold for cessation.
Ronaldson et al. (Wed,) studied this question.